The CDC recently warned clinicians of a potential 3- to 10- month shortage of Aplisol (tuberculin PPD), 1 of 2 tuberculin antigens approved by the US Food and Drug Administration for tuberculosis skin tests.
Par Pharmaceuticals, which manufactures the test, notified the CDC that they expect an interruption in the supply of 5-mL vials starting in June 2019 and 1-mL vials starting in November 2019 or sooner, according to the agency. Updated information about the supply of the drug will be posted on the FDA’s website.
Kuehn B. Tuberculin Antigen Shortage. JAMA. 2019;322(6):496. doi:10.1001/jama.2019.10855
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: